- The trend backdrop is active with a 9-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
KMTS
NASDAQ
Week ended 09 Oct 2026
Weekly Investor Report
Kestra Medical Technologies, Ltd. Common Stock · Healthcare · Medical Instruments & Supplies
Latest close
26.98 USD
-1.6%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 16.2% above the Trend Line and sits at 76.1% of its 52-week range. The latest completed week returned -1.6%, after a 18.1% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal.
Setup score
56
out of 100
Latest Close
26.98 USD
9 Oct 2026
1W Return
-1.6%
latest completed week
4W Return
18.1%
short-term follow-through
12W Return
10.5%
quarterly tape
Trend Breadth
53.8%
28 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.6%
Latest completed week; four-week move 18.1%.
Indicator stack
61/55
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
40 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 16.2% above the Trend Line and sits at 76.1% of its 52-week range. The latest completed week returned -1.6%, after a 18.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
18 Sep
25 Sep
2 Oct
9 Oct
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7312-week average 0.60
12-week confirmation
Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership3/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.73Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 18.1% over four weeks, 10.5% over 12 weeks, and 22.6% over one year. The current trend has remained active for 9 consecutive weeks.
Performance by holding period
Active trend streak9 weeks
Active weeks in one year28
Trend breadth53.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.33Latest activity-pressure read.
Pressure change-14.7%Four-week change in activity pressure.
Leadership-1.91Latest relative-leadership reading.
RS change85.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Oct 2026
Financial statements through 31 Jul 2026
Field coverage 85%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength13/100Blend of value, momentum, and quality. Underlying universe rank 88; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality12/100Profitability and accounting quality. Underlying universe rank 89; rank 1 is best.
Momentum70/100Medium-term price momentum. Underlying universe rank 31; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 15.1x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -7.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 53.9% Gross profit retained from each unit of revenue.
- Operating margin
- -134.5% Operating profit retained from revenue.
- Free-cash-flow margin
- -115.0% Free cash flow generated from revenue.
- Return on invested capital
- -46.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 60.7% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- -9.4% Net share repurchases relative to market value.
- Shareholder yield
- -9.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 40 relevant articles.
13 positive · 18 neutral · 9 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-10.1%Distance below the 52-week high.
13-week volatility8.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
17 Apr
15 May
12 Jun
10 Jul
7 Aug
4 Sep
9 Oct
Weeks higher11 of 2615 weeks finished lower.
Best week+32.6%Week of 26 Jun.
Worst week-13.8%Week of 24 Jul.
Latest week-1.6%Week of 9 Oct.
Shape of recent returns
Strong gains9
Modest gains2
Flat weeks0
Modest losses8
Sharp losses7
Recent vol8.3%13-week weekly-return volatility.
Base vol9.1%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew7.4% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average2.0%
Trend breadth63.0%
Trend63.0%active weekly trend signals
MD54.0%positive activity pressure
RS47.0%positive relative leadership
Four-week leaders
IndustryUS Medical Instruments & Supplies
4-week rank3 / 49
Group average-2.3%
Trend breadth53.1%
Trend53.1%active weekly trend signals
MD51.0%positive activity pressure
RS30.6%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape51/100
Trend, activity pressure, participation, and risk combine to a 51/100 tape read.
Indicator analysis62/100Latest 12-week confirmation: trend 9/12, activity pressure 12/12, relative leadership 3/12.
Activity pressure 0.73; 2 reversal markers Factors25/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 90; Small Cap Core rank 90 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 40 relevant articles.
Is Kestra Medical Technologies (KMTS) Undervalued Or Is Its Premium Already Priced In? Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 9 Oct 2026 | 26.98 USD | -1.6% | 23.21 USD | 22.63 USD | 0.33 | -1.91 | 1.6M | On |
| 2 Oct 2026 | 27.43 USD | 1.1% | 22.95 USD | 22.58 USD | 0.26 | -0.13 | 2.0M | On |
| 25 Sep 2026 | 27.14 USD | 11.1% | 22.80 USD | 22.52 USD | 0.26 | -0.75 | 1.3M | On |
| 18 Sep 2026 | 24.43 USD | 6.9% | 22.68 USD | 22.46 USD | 0.28 | -7.93 | 4.0M | On |
| 11 Sep 2026 | 22.85 USD | -10.5% | 22.75 USD | 22.44 USD | 0.39 | -13.45 | 1.2M | On |
| 4 Sep 2026 | 25.54 USD | -0.4% | 22.88 USD | 22.43 USD | 0.66 | -4.07 | 1.3M | On |
| 28 Aug 2026 | 25.64 USD | -5.0% | 22.88 USD | 22.39 USD | 0.81 | -3.06 | 891.4K | On |
| 21 Aug 2026 | 26.99 USD | -3.7% | 22.85 USD | 22.35 USD | 0.77 | 2.87 | 1.4M | On |
| 14 Aug 2026 | 28.02 USD | 6.1% | 22.77 USD | 22.29 USD | 0.55 | 4.40 | 1.5M | On |
| 7 Aug 2026 | 26.40 USD | 15.6% | 22.60 USD | 22.21 USD | 0.59 | 0.01 | 1.9M | Off |
| 31 Jul 2026 | 22.83 USD | 8.4% | 22.53 USD | 22.16 USD | 0.66 | -8.58 | 1.5M | Off |
| 24 Jul 2026 | 21.06 USD | -13.8% | 22.58 USD | 22.15 USD | 0.91 | -14.96 | 1.5M | Off |
| 17 Jul 2026 | 24.42 USD | -6.0% | 22.78 USD | 22.16 USD | 1.20 | -2.89 | 2.5M | Off |
| 10 Jul 2026 | 25.99 USD | -3.7% | 22.88 USD | 22.13 USD | 0.94 | -0.60 | 2.5M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.